This HTML5 document contains 36 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n7http://linked.opendata.cz/resource/drugbank/drug/DB03459/identifier/pdb/
n9http://bio2rdf.org/drugbank:
n11http://linked.opendata.cz/resource/drugbank/drug/DB03459/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n12http://linked.opendata.cz/resource/drugbank/drug/DB03459/identifier/pubchem-substance/
n13http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n6http://linked.opendata.cz/resource/drugbank/drug/DB03459/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB03459
rdf:type
n3:Drug
n3:description
N-(phosphonacetyl)-L-aspartic acid is a solid. This compound belongs to the n-acyl-alpha amino acids. These are compounds containing an alpha amino acid which bears an acyl group at his terminal nitrogen atom. This substance is known to target aspartate carbamoyltransferase catalytic chain and CAD protein.
n3:group
experimental
owl:sameAs
n9:DB03459 n13:DB03459
dcterms:title
N-(phosphonacetyl)-L-aspartic acid
adms:identifier
n6:DB03459 n7:PAL n11:46936683 n12:46507931
n3:IUPAC-Name
n4:271B4A24-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4A2A-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4A29-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4A26-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4A27-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4A28-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4A22-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4A20-363D-11E5-9242-09173F13E4C5 n4:271B4A23-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4A21-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4A30-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4A31-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4A2B-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4A2C-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4A2E-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4A2D-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4A2F-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
51321-79-0
n3:Bioavailability
n4:271B4A35-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4A37-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4A38-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4A34-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4A33-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4A36-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4A25-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4A32-363D-11E5-9242-09173F13E4C5